Related Experiment Video
Updated: Oct 23, 2025
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
5.4K
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention:
Giulio G Stefanini1,2, Carlo Briguori3, Davide Cao4
1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan 20090, Italy.
European Heart Journal
|August 23, 2021
Summary
Ticagrelor monotherapy in chronic kidney disease (CKD) patients undergoing percutaneous coronary intervention (PCI) significantly reduced bleeding events compared to dual therapy. This approach did not increase ischemic event rates, offering a safer option for CKD patients.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Chronic kidney disease (CKD) is prevalent in patients undergoing percutaneous coronary intervention (PCI).
- Optimal antiplatelet therapy in CKD patients post-PCI remains a critical clinical question.
Purpose of the Study:
- To evaluate the safety and efficacy of ticagrelor monotherapy versus ticagrelor plus aspirin in patients with and without CKD undergoing PCI.
- To assess the impact of renal function on treatment outcomes in the TWILIGHT trial.
Main Methods:
- Prespecified subanalysis of the TWILIGHT trial, including patients with drug-eluting stent implantation and high-risk criteria.
- Patients received ticagrelor plus aspirin for 3 months, then were randomized to ticagrelor monotherapy or ticagrelor plus aspirin for 12 months.
- CKD defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m².
Main Results:
- Ticagrelor monotherapy significantly reduced major bleeding (BARC types 2, 3, or 5) in both CKD (4.6% vs. 9.0%) and non-CKD (4.0% vs. 6.7%) patients, with a greater absolute risk reduction in CKD patients.
- No significant differences in rates of death, myocardial infarction, or stroke were observed between the groups, regardless of CKD status.
- P-interaction for bleeding was 0.508 and for ischemic events was 0.111, indicating no significant differential treatment effect based on CKD presence.
Conclusions:
- Ticagrelor monotherapy is a safe and effective strategy for CKD patients undergoing PCI, reducing bleeding risk without compromising ischemic protection.
- The findings support a tailored antiplatelet approach considering renal function in high-risk PCI patients.
Related Concept Videos
01:28Cardiac Catheterization I: Pre-Procedure Overview
303
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
303
01:28Acute Coronary Syndrome IV: Interprofessional Care
57
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
57
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
291
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
291
01:27Coronary Artery Disease V: Interprofessional Care
72
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
72
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
98
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
98
01:27Peripheral Artery Disease III: Interprofessional Care
73
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
73